Item: Capital Cell
Rating: 0.0
Author: Crowdinform

On the Capita cell, you can invest in shares of medical startups with x10+ return potential.

Capital Cell - Risk and return review

Return level i

Very High

Capital sells aim for high-return projects, and potential returns are in the range from 1000% to 3000% and more. Total portfolio growth is 2.7. times.

Risk Return Level i

Medium

A company offering high-risk and high-return projects, thus, in a 10-year company, in total grew 270% or on average 27% per year.

Risk Return Level i

Good

Capital Cell provides expert reviews which allow selecting the best projects, and it results in portfolio growth 2.7 times. But given that the company focuses on early-stage Med tech companies, risk remains high.

Capital Cell – Platform statistics 2026

Information updated at: 25 Jan 2026

151 projects funded

144.0M EUR funded amount

Capital Cell – Pros & Cons

PROS

The platform supports key European languages and accepts investors from the EU

Secondary market allowing early exit

Independent expert review

One of the best project descriptions and data in the market (estimated returns and exit year)

In a 10-years, the total portfolio growth was 270% or on average 27% per year.

CONS

Not a big project supply

No detailed information about portfolio performance (exit amounts, etc) and no summary, only project status presented.

About Capital Cell

Capital Cell selects promoters through a multi-step screening focused on scientific, commercial, and legal quality. Promoters must submit detailed project, team, and financial information, which is reviewed by Capital Cell and its expert BioExpert Network for feasibility and investment merit. If approved, the promoter agrees on campaign terms and completes legal and financial due diligence. Before a public launch, a private pre-campaign must demonstrate traction, including a committed lead investor (around 15%), at least 20% of the target reserved, and interest from a minimum number of investors. Capital Cell may refuse publication if documentation, investor interest, or the promoter’s promotional capacity is insufficient.

Regulation

License / Regulation: CAPITAL CELL licensed under European Crowdfunding Service Providers (ECSP) regulation

Functionality

Autoinvest: No

Deal rating: No

Secondary market: No

For Investors

Limitations: In principle, any citizen or company of any country that is not on the list of tax havens of the Spanish government. However, in case of natural person it is required to have the NIE and in case of company, Spanish CIF.

Minium investment: 100 EUR

For Fund Seekers

Useful Information

How does Capital Cell work?

Capital Cell operates as an Equity crowdfunding platform offering investors to invest in startups and early-stage companies through acquiring company shares. On the other hand offering companies am alternative fundraising tool to raise funds from a large pool of investors.

What investments does Capital Cell offer?

On Capital Cell you can invest in European startups from healthcare and biotech industries

What is a risk when investing on Capital Cell ?

When investing on Capital Cell you invest in early-stage companies which makes it a high-risk investment since statistically 9 of 10 early-stage companies fail. You as an investor have to carefully evaluate such investments including product, product-market fit, company team and their ability to successfully develop a company, total addressable and reachable market and company growth potential, and other risks depending on business specifics.